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Objective—To examine change in health-related quality of life (HRQoL) in association with
clinical outcomes of neuropsychiatric (NP) events in SLE.
Methods—An international study evaluated newly diagnosed SLE patients for NP events
attributed to SLE and non-SLE causes. Outcome of events was determined by physician-
completed 7-point scale and compared to patient-completed SF-36 questionnaires. Statistical
analysis used linear mixed-effects regression models with patient specific random effects.
Results—274 patients (92% female; 68% Caucasian), from a cohort of 1400, had ≥ 1 NP event
where the interval between assessments was 12.3 ± 2 months. The overall difference in change
between visits in mental component summary (MCS) scores of the SF-36 was significant
(p<0.0001) following adjustments for gender, ethnicity, center and previous score. A consistent
improvement in NP status (N=295) was associated with an increase in the mean(SD) adjusted
MCS score of 3.66(0.89) in SF-36 scores. Between paired visits where NP status consistently
deteriorated (N=30), the adjusted MCS score decreased by 4.00(1.96). For the physical component
summary (PCS) scores the corresponding changes were +1.73(0.71) and −0.62(1.58) (p<0.05)
respectively. Changes in SF-36 subscales were in the same direction (p<0.05; with the exception
of role physical). Sensitivity analyses confirmed these findings. Adjustment for age, education,
medications, SLE disease activity, organ damage, disease duration, attribution and characteristics
of NP events did not substantially alter the results.
Conclusion—Changes in SF-36 summary and subscale scores, in particular those related to
mental health, are strongly associated with the clinical outcome of NP events in SLE patients.
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The prevalence of neuropsychiatric (NP) disease in patients with systemic lupus
erythematosus (SLE) varies from 21% to 95% and recent studies indicate a frequency at the
lower end of this range (1–5). There is a spectrum of potential NP events as reflected by the
American College of Rheumatology (ACR) case definitions for 19 NP syndromes (6). Only
13% to 38% of all NP events are attributable to SLE depending upon the stringency of the
decision rules for determining attribution (7–11). Regardless of attribution, both cross-
sectional (3, 8) and longitudinal (7, 11) studies have demonstrated that NP events are
independently associated with lower self-report health related quality of life (HRQoL).
Clinical trials are necessary to address the optimal management of NP events in SLE
patients. Challenges to planning and executing such studies include the lack of validated
outcome measures for the diverse NP events. Specific outcomes for individual NP events in
addition to generic outcomes to allow a comparison with change across all NP events and
other manifestations of SLE are required. The objective of the present study was to
determine if the SF-36 is an appropriate outcome measure for the study of NP events in
SLE. Specifically, we examined the association between changes in patient derived SF-36
summary and subscale scores and physician determined outcomes of NP events in an
international, longitudinal cohort study of NP events in SLE patients.
Patients and Methods
Research network
This prospective study was performed by the Systemic Lupus International Collaborating
Clinics (SLICC) (12) between October 1999 and May 2009. The study was approved by the
Capital Health Research Ethics Board, Halifax, Nova Scotia, Canada and by the institutional
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research ethics boards of participating centers in accordance with the Declaration of
Helsinki’s guidelines for research in humans.
Patients
Patients fulfilled the American College of Rheumatology (ACR) classification criteria for
SLE (13) and provided written informed consent. The date of diagnosis was the time when
four or more of the ACR criteria were first recognized and patients were enrolled up to 15
months thereafter. Data collection included age, gender, ethnicity, education, medication
use, SLE Disease Activity Index (SLEDAI) (14) and SLICC/ACR damage index (SDI) (15).
Health related quality of life (HRQOL) was measured by the SF-36 (16). Laboratory data
included a complete blood count, serum creatinine, urinalysis, anti-dsDNA, C3 and C4.
Neuropsychiatric (NP) events
An enrollment window within which all NP events were captured extended from 6 months
prior to the diagnosis of SLE up to the enrollment date. NP events were characterized using
the ACR nomenclature and case definitions for 19 NP syndromes (6). Screening for NP
syndromes was done by clinical evaluation and investigations were performed if clinically
warranted.
Patients were reviewed annually following enrollment with a 6-month window around the
anticipated assessment date. New NP events since the previous study visit and their
attribution were determined. For the purpose of this study, patients were required to have an
NP event(s) at one assessment, a physician defined outcome of the event at a subsequent
assessment and a completed SF-36 questionnaire at both assessments. Those patients who
developed a new or recurring NP event(s) between these assessments were excluded as such
events would not have been reflected in the previous SF-36 scores.
Supplementary information was recorded as per the ACR glossary for NP syndromes (6) to
identify other potential causes (“exclusions”) or contributing factors (“associations”) for
each of the NP events (6). These “non-SLE factors” were used in part to determine the
attribution of NP events. Patients could have more than one type of NP event and repeated
episodes of the same event within the enrollment window or at follow-up annual
assessments were recorded once. The date of onset of the NP event was the time of the first
episode within the assessment period.
Attribution of NP events
All NP events were recorded and attribution to SLE was determined by decision rules of
different stringency (models A and B) as described in detail elsewhere (8, 10). NP events
which fulfilled the criteria for model A (the most stringent) or for model B (the least
stringent) were attributed to SLE. By definition, all NP events attributed to SLE using model
A were included in the group of NP events attributed to SLE using model B. Those events
which did not fulfill these criteria were attributed to non-SLE causes.
Outcome of NP events
A physician generated 7-point Likert scale for NP events comparing the change in NP status
between the onset of the event and time of study assessment was available for each NP event
(1=patient demise, 2=much worse, 3=worse, 4=no change, 5=improved, 6=much improved,
7=resolved). Due to the occurrence of multiple concurrent NP events in the same patient,
there were 5 possible patient level outcomes for each pair of assessments: 0 – no difference
(single event) or no consistent change (multiple events) in NP status; 1 – all events improve;
2 - all events worsen; 3 – some but not all events improve and none worsen; 4 – some but
not all events worsen and none improve. For the purpose of the primary analyses the
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patients’s paired visits with outcomes 3 and 4, of which there were only 71, were combined
with those patients paired visits with NP events without a consistent change, outcome 0.
A second outcome measure was based on a patient generated SF-36 questionnaire which
provided mental (MCS) and physical (PCS) component summary scores, subscale scores
(16) and SF-6D scores (17). The difference between the scores at the paired visits was used
as the response variable. The physician determined outcome of NP status defined
explanatory variables for the regression analyses, which were also adjusted for other
relevant variables. The SF-36 scores were not available to the physicians at the time of their
evaluation of NP status.
Statistical analyses
Linear mixed-effects models with random intercepts were used so that patient/visits
involving the same patient are not assumed to be independent. Specifically, conditional on
this random intercept, we assume the variance of the change in health scores is constant and
that the patients’ scores are uncorrelated.
Results
Patients
A total of 274 patients (20% of all patients) who had ≥ 1 NP event with a documented
clinical outcome and 2 completed SF-36 questionnaires at the appropriate assessments were
identified from a cohort of 1400 newly diagnosed SLE patients. Patients were predominantly
women (92.3%) with a mean ± SD age of 37.1 ± 13.2 years and a wide ethnic distribution
although predominantly Caucasian (Table 1).
At enrollment the mean disease duration was 5.9 ± 4.0 months. The prevalence of individual
ACR classification criteria at baseline reflected an unselected patient population and
“neurologic disorder”, which includes seizures and psychosis only, was present in 25 (9%)
of the 274 patients. The mean SLEDAI and SDI scores at enrollment were 5.1 ± 5.4 and
0.31 ± 0.70 respectively indicating moderate global disease activity and minimal cumulative
organ damage respectively. Therapy at enrollment reflected the typical range of lupus
medications. The mean interval between assessments was 12.3 ± 1.94 months.
The characteristics of the patients that did not contribute to the analysis were generally
similar to those that did. For example, 88% were female and their age at enrollment was
33.6 ± 13.3 years. Their mean SLEDAI and SDI scores at enrollment were 5.5 ± 5.5 and
0.29 ± 0.75. However some regions, such as Canada for example, were under-represented in
the sample that did not contribute to the analysis (Canada 19%; US 30%; Mexico 16%;
Europe 23%; Asian 13%) and this has some implications for their ethnicity (Caucasian 42%;
Hispanic 20%; Asian 19%; Black 16%; other 4%). All analyses adjust for region and
ethnicity effects and hence the main impact of any difference would be to limit the power
for testing interaction effects.
Frequency, attribution of NP events
In 274 patients there were 587 pairs of patient visits that met the criteria in order to
contribute to the analysis. One hundred and twenty four of these patients contributed a single
pair of visits and 150 contributed two or more pairs. Multiple events at the previous study
visit were common and, in total, 912 events were included in the analysis, which
encompassed 17 of the 19 ACR case definitions (Table 2); Guillain-Barré syndrome and
aseptic meningitis did not occur in any patient.
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The most frequent events were headache (437 (48%) of 912 events), mood disorders (182
(20%)), cognitive dysfunction (63 (6.9%)), anxiety disorder (58 (6.4%)), cerebrovascular
disease (31 (3.4%)), polyneuropathy (31 (3.4%)), mononeuropathy (31 (3.4%) and seizures
(26 (2.9%)). The remaining 11 NP syndromes had a prevalence of less than 6% of all NP
events.
NP events attributed to SLE using alternate attribution models varied from 15% (model A)
to 28% (model B) of the 912 NP events (Table 2). Of these, 91% affected the central
nervous system and 9% involved the peripheral nervous system; 83% were diffuse and 17%
were focal events. Using attribution models A and B respectively, the most frequent NP
events attributed to SLE were mood disorders (24–30%), mononeuropathy (15–12%),
cerebrovascular disease (14–12%) and cognitive dysfunction (10–15%).
Physician determined outcome scores for NP events
A summary of NP outcomes at individual patient visits is provided in Table 3.
Change in SF-36 summary and subscale scores and outcome of NP events
The overall difference in the change in MCS scores in 3 patient groups (all NP events
improved, all NP events deteriorated and NP events without a consistent change) reached
statistical significance (p<0.0001) following adjustments for gender, ethnicity, research
center and previous SF-36 MCS score (Table 4).
Patients whose NP status consistently improved (N=295) had their estimated adjusted mean
(SD) MCS score increase by 3.66 (0.89) more than in patients without a consistent change
(N=262) over the same interval. In contrast, for patients whose NP status consistently
deteriorated (N=30), the MCS score decreased by an estimated adjusted mean of 4.00 (1.96).
For the SF-36 physical component summary (PCS) scores the corresponding changes
associated with improvement and deterioration in NP status were +1.73 (0.71) and −0.62
(1.58) (p<0.05) respectively. The results are also shown for SF-6D (29) in Table 4, and
qualitatively similar results are obtained using this measure as the SF-36 MCS. Sensitivity
analyses were conducted by modifying the definition of clinical change in NP status.
Expanding the definition of improvement in NP status, by using all 5 categories of change as
in table 3, and refitting the models, did not substantially change the estimated effects
associated with consistent improvement or worsening (Online supplementary file Table SI).
Changes in the eight SF-36 subscales were in the same direction as the summary scores
(p<0.05; with the exception of role physical)) (Table 5). Unadjusted mean SF-36 subscale
scores for the patient/visits for each of the three groups in Table 4 are shown in Figure 1
using a ‘spydergram’ (19).
Additional variables at the first of the two visits were considered for adjustment: age,
education, medications, global SLE disease activity, cumulative organ damage, attribution
of NP events, diffuse/focal classification of NP events and disease duration. Since headache
was such a common event, whether or not it was present was also investigated as a potential
variable for adjustment. In each instance the additional variables were entered into the
statistical model both with and without an interaction with change in NP status. Again, no
substantial changes were observed.
For the MCS, the only notable predictor was SLEDAI (non-NP score estimated without the
NP variables) where there was evidence of an interaction with change in NP status (p<0.01,
2df test). The dominant interaction with the change in SF-36 score occurred in patients
whose NP status deteriorated compared to patients without a consistent change. The mean
change in SF-36 MCS was estimated to decrease by approximately 2 points for each 1 unit
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increase in SLEDAI. Since the standard deviation of SLEDAI (non-NP) across the entire
sample of patient visits is 4.4, this could translate into an important quantitative effect.
However, there were only 30 patients who had a consistent deterioration in NP status
between their two assessments (table 2) and hence this estimate is uncertain, with an
approximate 95% confidence interval of (0.7, 3.7) and should be interpreted with some
caution. The comparable (non-significant) estimated effect of SLEDAI (non-NP) on the
mean difference in SF-36 MCS score between patients with improved NP status and those
with no consistent change was estimated to be a decrease of 0.3 per unit change in SLEDAI
(non-NP) with a confidence interval of (–0.1,0.7).
For PCS, the only strong additional potential predictor was the patients’ age (p<0.0001). A
strong and negative association between age and change in PCS score was observed as one
might expect but this did not affect estimates linked to the change in NP status.
Discussion
Different outcome measures have been used in the assessment of patients treated for
NPSLE. These include clinical assessment (20, 21), neuropsychological evaluation of
cognition (22, 23) and neuroimaging (21, 24). Although NP events in SLE patients are
known to impact negatively on HRQoL (3, 7, 8, 11), the use of standardized measures of
HRQoL have not been validated in the assessment of change in NP status in SLE. We have
examined the change in SF-36 summary and subscale scores in SLE patients who have had a
clinically significant change in NP status over 1 year. In essence we examined the face
validity of SF-36 scores for measuring the clinical outcome of NP events. The results
indicate that SF-36 scores, in particular those which reflect self-report mental health, change
in the appropriate direction in association with both clinical improvement and deterioration
in a variety of NP events.
The study was conducted within a large, international, inception cohort of SLE patients. The
characteristics of the entire cohort have been published elsewhere (7, 8) and are similar to
the subset of patients who were eligible for the current analysis. In contrast to many
previous studies of NPSLE, ours was prospective with the specific objective of identifying
the characteristics, attribution and outcome of NP events using a predefined annual data
collection protocol. The multi-center, international study design provides a basis for
assuming that our findings are applicable to the broader community of SLE patients.
Predefined outcomes in studies of therapeutic interventions for NPSLE have been variable
and largely determined by the specific NP event under study. Thus, in the evaluation of
interventions to improve cognitive performance (22, 23) sequential neuropsychological
assessment was the primary outcome of brain health. The efficacy of treating neurological
manifestations of NPSLE have been determined by sequential neuroimaging alone (24, 25)
or used in combination with clinical variables to provide a composite outcome (26, 27). To
our knowledge none of the previous approaches have been validated. Given the diversity of
NP events in SLE and the lack of clinical trial evidence to support specific interventions,
there is a need to determine optimal outcome measures.
Rather than developing a measure for change in a specific NP manifestation, we wished to
validate a change in patient self-report HRQoL as a generic measure for improvement and
deterioration in NP status over time. This was a logical step following upon the previous
work by ourselves and others showing that NP events have been associated with lower
SF-36 scores in both cross-sectional and longitudinal studies of SLE patients (3, 7, 8, 11,
28). Physician determined change in NP status was significantly correlated with change in
patient self-report SF-36 scores. Not surprisingly the magnitude of change in SF-36 scores
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was greater for the mental component summary score than the physical score. Although the
SF-36 may be affected by other variables such as global disease activity, cumulative organ
damage and concurrent medications, adjustment for these and other variables in the analysis
did not negate the association with NP events with the possible exception of SLE disease
activity outside of the nervous system in patients who had deterioration in NP status. It was
also apparent that attribution of NP events to SLE and non-SLE causes did not change the
results, indicating that this is a valid outcome for all NP events in SLE patients, even though
the majority of events are not attributed to SLE.
Previous studies have indicated that in SLE patients the minimum clinically important
difference (MCID) for SF-36 MCS and PCS summary scores is 2.5 – 5.0 and for subscale
scores is 5.0–10.0 (29, 30). The adjusted differences in SF-36 scores in our analysis, which
would be expected to be less than unadjusted changes, fall within the MCID for the MCS
score and most of the subscale scores of the SF-36. Furthermore the estimated standard error
associated with a single observation of a change in SF-36 summary scores between visits,
with adjustment for gender, ethnicity, institution and previous score, is approximately 10.
Therefore if a clinical trial was designed to detect a difference in mean change of 3.66 (the
mean difference in MCS scores between patients whose NP events all improve compared to
patients without a consistent change in NP events) between two equal sized treatment
groups, the sample size to achieve 80% power when testing at the 5% level would be
approximately 120 patients per group. If no adjustment for previous score was planned, then
approximately 155 patients per group would be required.
There are limitations to the current analysis. First, some NP events were either absent or
underrepresented which emphasizes the relatively low frequency of some NP
manifestations. In previous studies (2–5, 18) approximately half of the 19 NP syndromes in
the ACR case definitions occurred in only 1–2% of SLE patients. Second, patients with
severe or very active NP disease may have been unable to complete the SF-36 at the time
when NP disease was at it worst. In such cases, the magnitude of change in scores would
likely have been even higher that what was found. Third, some psychosocial variables such
as fibromyalgia, helplessness and low socioeconomic status were not available in our
dataset. Fourth, the physician assessment of some NP events (e.g. headache and mood
disorders) is dependent in part on patients’ subjective complaints which are potential
confounders in the interpretation of parallel changes in SF-36 scores. However, for those NP
events (e.g. cerebovascular disease, myelopathy and neuropathies) with more objective
outcomes, there were comparable changes in SF-36 scores. Finally, the small number of
patients (30) with outcome 2 (all worsen) for NP events, which may have been due to the
lengthy interval between assessments that provided ample time for treatment, limits the
gereralizability of the findings for this group.
Despite these limitations the results of our study indicate that changes in SF-36 summary
and subscale scores, in particular those related to mental health, are strongly associated with
the clinical outcome of NP events in SLE patients. Thus, changes in SF-36 should be an
outcome measure in any clinical trial or study which examines the efficacy of therapeutic
interventions for NP disease in SLE patients.
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Unadjusted mean SF-36 subscale scores in patient/visits in three groups: patients lacking a
consistent change in NP events (top panel; Outcomes 0, 3 and 4; N=262); patients whose NP
events all improve (middle panel; Outcome 1; N=295); patient whose NP events all worsen
(bottom panel; Outcome 2; N=30). Dashed lines denote subscale scores from the first visit of
the pair and solid lines denote the second set of scores. The SF-36 subscales are BP = Bodily
pain, RP = Role physical, PF = Physical function, MH = Mental health, RE = Role emotion,
SF = Social function, VT = Vitality, GH= General health.
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Table 1
Demographic and clinical manifestations of 274 SLE patients





Age (years) (mean ± SD) at enrollment 37.1 ± 13.1











Post secondary education (%) 67
Disease duration (months) (mean ± SD) at enrollment 5.9 ± 4.0
Number of ACR criteria (mean ± SD) 4.8 ±1.0












SLEDAI score (mean ± SD) at enrollment 5.1 ± 5.4





Pulse IV corticosteroids 4
Anticoagulants including warfarin, ASA 25
Antidepressants 19
Antiseizure drugs 9
Other psychoactive drugs 7
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Table 4
The mean (±SEM) difference* in change in SF-36 mental component summary (MCS), physical component
summary (PCS) and SF-6D scores between patients visits whose NP events all improve (1) or all worsen (2)
compared to patients lacking a consistent change in NP events (0, 3, 4).
MCS PCS SF-6D
All NP events improve (N=295) (1) 3.66 ± 0.89 1.73 ± 0.71 0.035 ±0.009
NP events without consistent change (N=262) (0, 3, 4) 0 0 0
All NP events worsen (N=30) (2) −4.00 ± 1.97 −0.62 ± 1.58 −0.029 ± 0.019
Global significance <0.0001 0.035 <0.0001
*
adjusted for previous SF-36 score and other demographic variables.
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Table 5
The mean (±SEM) difference* in change in SF-36 subscale scores between patient visits whose NP events all






(1) 10.58 ± 3.46 7.50 ± 1.92 5.77 ± 1.56 6.52 ± 1.45
(0, 3, 4) 0 0 0 0
(2) −11.06 ± 7.67 −5.67 ± 4.24 −4.53 ± 3.43 −6.68 ± 3.19
Global









(1) 6.17 ± 1.75 4.88 ± 1.29 5.34 ± 1.54 6.77 ± 3.28
(0, 3, 4) 0 0 0 0
(2) −3.10 ± 3.90 −6.18 ± 2.90 −6.71 ± 3.46 −3.69 ± 7.28
Global
Significance 0.0006 <0.0001 0.0001 0.075
*
adjusted for previous SF-36 score and other demographic variables.
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